Who We Are and What We Do
At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments.
GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases particularly where there is high unmet need. Since the company’s inception in 2003, we have developed a robust, diversified product pipeline.
We are pleased now to be a public company traded on the NASDAQ under the symbol GLYC.
September is National Sickle Cell Disease
GlycoMimetics Honors the Sickle Cell Community
This month, and every month, GlycoMimetics honors those affected by sickle cell disease, their families, and their caregivers. As the discoverers of rivipansel (GMI-1070), an investigational drug which is currently being studied in partnership with Pfizer to treat vaso-occlusive crisis (VOC)—or pain crisis—of sickle cell disease, we recognize the critical need for more treatment options. We thank the sickle cell community for its ongoing commitment to educate and advocate on behalf of those impacted by the disease.